Ono Pharmaceutical (OTCMKTS:OPHLF) Announces Quarterly Earnings Results

Ono Pharmaceutical (OTCMKTS:OPHLF) released its earnings results on Monday. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.29 by $0.11, Zacks reports. Ono Pharmaceutical had a return on equity of 6.13% and a net margin of 9.75%.The company had revenue of $892.70 million during the quarter, compared to analyst estimates of $727.58 million.

Ono Pharmaceutical Stock Performance

Shares of OTCMKTS OPHLF opened at $15.22 on Tuesday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.50 and a current ratio of 2.99. The business’s 50-day simple moving average is $13.65 and its 200-day simple moving average is $12.20. The firm has a market cap of $7.15 billion, a price-to-earnings ratio of 21.74 and a beta of 0.25. Ono Pharmaceutical has a 52 week low of $9.20 and a 52 week high of $15.22.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.